<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05126303</url>
  </required_header>
  <id_info>
    <org_study_id>20-ROS-05</org_study_id>
    <nct_id>NCT05126303</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery</brief_title>
  <acronym>AKITA</acronym>
  <official_title>A Phase 2, Randomized, Placebo-Controlled, Double-Blind, Adaptive, Parallel Group Clinical Study to Evaluate the Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guard Therapeutics AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guard Therapeutics AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates RMC-035 compared to placebo for the prevention of acute kidney injury&#xD;
      (AKI) in subjects who are at high risk for AKI following cardiac surgery. Half of the&#xD;
      subjects will receive RMC-035 and the other half will receive placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, randomized, double-blind, adaptive, parallel group clinical study that&#xD;
      will evaluate RMC-035 compared to placebo in subjects at high risk for acute kidney injury&#xD;
      (AKI) following cardiac surgery. Subjects are randomized in a 1:1 ratio.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, adaptive, parallel group</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects developing AKI (as defined per KDIGO criteria)</measure>
    <time_frame>72 hours</time_frame>
    <description>AKI based on Serum Creatinine and/or Urine Ooutput per KDIGO definition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>90 days</time_frame>
    <description>Nature, frequency and severity of treatment-emergent adverse events</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">268</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>RMC-035</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RMC-035 is a concentrate (6.0 mg/mL) for solution for infusion for IV administration.&#xD;
Dosing will be based on renal function at Day -1: Subjects with eGFR ≥60 mL/min/1.73m2 will receive 1.3 mg/kg (per dose) for the first and second dose, followed by 0.65 mg/kg (per dose) for the third, fourth and fifth dose, while subjects with eGFR &gt;30 and &lt;60 mL/min/1.73m2 will receive 0.65 mg/kg (per dose) for all five doses Dosing occurs at time 0 and then after 6, 12, 24 and 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical to RMC-035 arm except that the placebo contains no active ingredient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RMC-035</intervention_name>
    <description>Concentrate for Solution for Infusion</description>
    <arm_group_label>RMC-035</arm_group_label>
    <other_name>ROSgard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Concentrate for Solution for Infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. IRB/IEC approved Informed Consent obtained&#xD;
&#xD;
          2. Ability to understand and comply with the study requirements and able to provide&#xD;
             written informed consent&#xD;
&#xD;
          3. Age ≥18 and &lt;85 years&#xD;
&#xD;
          4. Estimated glomerular filtration rate (eGFR) is ≥30 mL/min/1.73 m2&#xD;
&#xD;
          5. Subject is scheduled for non-emergent CABG surgery and/or valve surgery and/or&#xD;
             ascending aorta aneurysm surgery with use of CPB, and AKI risk factors are present at&#xD;
             screening&#xD;
&#xD;
          6. Female subject is not of child-bearing potential, or agreeing not to become pregnant&#xD;
&#xD;
          7. Female subject must not be breastfeeding&#xD;
&#xD;
          8. Female subject must not donate ova&#xD;
&#xD;
          9. Male subject and their female spouse/partner(s) who are of childbearing potential must&#xD;
             be using a highly effective form of birth control&#xD;
&#xD;
         10. Male subjects must not donate sperm&#xD;
&#xD;
         11. Subject agrees not to participate in another interventional study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Medical condition that makes the subject unsuitable for study participation&#xD;
&#xD;
          2. Scheduled for emergent surgeries (eg, aortic dissection)&#xD;
&#xD;
          3. Scheduled for CABG and/or valve surgery and/or ascending aorta aneurysm surgery&#xD;
             combined with additional non-emergent cardiac surgeries (eg, congenital heart defects)&#xD;
&#xD;
          4. Scheduled to undergo transcatheter aortic valve implantation (TAVI) or transcatheter&#xD;
             aortic valve replacement (TAVR), or off-pump surgeries or left ventricular assist&#xD;
             device (LVAD) implantation&#xD;
&#xD;
          5. Experiences a cardiogenic shock or hemodynamic instability which require inotropes or&#xD;
             vasopressors or other mechanical devices within 24 hours prior to surgery&#xD;
&#xD;
          6. Requirement for defibrillator or permanent pacemaker, mechanical ventilation, IABP,&#xD;
             LVAD, or other forms of mechanical circulatory support (MCS)&#xD;
&#xD;
          7. Diagnosed with AKI (as defined by KDIGO criteria) within 3 months prior to surgery&#xD;
&#xD;
          8. Required cardiopulmonary resuscitation within 14 days prior to cardiac surgery&#xD;
&#xD;
          9. Ongoing sepsis or an untreated diagnosed clinically significant infection (viral or&#xD;
             bacterial)&#xD;
&#xD;
         10. Total bilirubin or alanine aminotransferase (ALT) or aspartate aminotransferase (AST)&#xD;
             ≥ 2 times the upper limit of normal (ULN)&#xD;
&#xD;
         11. History of solid organ transplantation&#xD;
&#xD;
         12. History of renal replacement therapy (RRT)&#xD;
&#xD;
         13. Medical condition which requires active immunosuppressive treatment&#xD;
&#xD;
         14. Ongoing chemotherapy or radiation therapy for malignancy that may have an impact on&#xD;
             kidney function&#xD;
&#xD;
         15. Received an investigational medicinal product within the last 90 days (or within 5&#xD;
             half-lives of the investigational drug, whichever is longer)&#xD;
&#xD;
         16. Subject has a known allergy to RMC-035 or one of its constituents, or has previously&#xD;
             received RMC-035&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Agervald, MD</last_name>
    <role>Study Director</role>
    <affiliation>Guard Therapeutics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Zarbock, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Muenster University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Thuresson</last_name>
    <phone>+46733319438</phone>
    <email>sara.thuresson@guardtherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr Mueller</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana Ohio Heart</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr Scavo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bryan Heart</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr Thompson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rochester Regional Health - Rochester General Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr Corteville</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr Swaminathan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Scott and White Research Institute - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr Hebeler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia (UVA) Health - University Hospital</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr Teman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Health Care - Aurora St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr Kress</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Münster University Hospital</name>
      <address>
        <city>Münster</city>
        <zip>DE-481 49</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr Zarbock, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

